BioSpace News Archive

The winning solution, Prometeo, will be deployed through a companion IBM program that is dedicated to tackling some of society’s most pressing challenges with IBM open source-powered technologies

PPF Group, the majority owner of SOTIO, invests $6.5 million as part of MaveriX Oncology’s $20 million Series A financing round.

The second annual DaVita Day of Music hosts pop-up concerts inside DaVita centers

Cerecor Inc. announced that it has entered into an asset purchase agreement with AYTU BioScience, Inc. to sell Cerecor’s Pediatric Portfolio in a deal valued in excess of $32 million.

Dr. Reddy’s Laboratories Ltd. will announce results for the second quarter ended September 30, 2019 on Friday, November 1, 2019 after the Board Meeting.

Matinas BioPharma Holdings, Inc. announced that it has initiated its Phase 2 EnACT clinical study, which will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals.

CEQUA™ (cyclosporine ophthalmic solution) 0.09% for topical ophthalmic use is the first and only approved cyclosporine treatment delivered with NCELL™ technology

Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology.

YONDELIS® (trabectedin) is a globally recognised treatment for patients with advanced soft tissue sarcoma as second-line therapy and beyond, but has been difficult for Australians to access

Abzena announced the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive leadership team.